Abstract Search

ea0046p11 | (1) | UKINETS2016

Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews

Anthony Lowell , Horsch Dieter , Ervin Claire , Kulke Matthew H. , Pavel Marianne , Bergsland Emily , Caplin Martyn , Oberg Kjell , Warner Richard , Kunz Pamela , Metz David C. , Pasieka Janice , Pavlakis Nick , DiBenedetti Dana , Haydysch Emily , Yang Qi Melissa , Jackson Shanna , Arnold Karie , Law Linda , Lapuerta Pablo

Background: Telotristat etiprate (TE), an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome (CS) by reducing serotonin production. TE was evaluated in TELESTAR, a phase 3 study; the primary endpoint showed significant reductions in bowel movement (BM) frequency for 2 TE dosages + standard of care (SOC) vs. SOC. TELESTAR patients had CS inadequately controlled on somatostatin analog therapy with ≥4 BMs per day. They were interviewed about base...

0 shares

Endocrine Abstracts

Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews

BiosciAbstracts